Immunome Inc
IMNM10.300USD
+0.350+3.52%
Handelsschluss 08/22, 16:00（ET）Kurse um 15 Minuten verzögert
896.23MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Immunome Inc Unternehmen
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.
Unternehmensinformationen
BörsenkürzelIMNM
Name des UnternehmensImmunome Inc
IPO-datumOct 02, 2020
CEODr. Clay B. Siegall, Ph.D.
Anzahl der mitarbeiter118
WertpapierartOrdinary Share
GeschäftsjahresendeOct 02
Addresse18702 N. Creek Parkway
StadtBOTHELL
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl98011
Telefon16103213700
Websitehttps://immunome.com/
BörsenkürzelIMNM
IPO-datumOct 02, 2020
CEODr. Clay B. Siegall, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Ms. Sandra G. Stoneman
Ms. Sandra G. Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Chief Legal Officer, General Counsel, Corporate Secretary
--
--
Dr. Phil Tsai
Dr. Phil Tsai
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Sandra M Swain, M.D.
Dr. Sandra M Swain, M.D.
Independent Director
Independent Director
--
--
Dr. Bob Lechleider, M.D.
Dr. Bob Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.73K
+38.44%
Umsatzaufteilung
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
2.93M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
9.51%
Fidelity Management & Research Company LLC
7.09%
BlackRock Institutional Trust Company, N.A.
5.94%
Redmile Group, LLC
5.60%
Enavate Sciences GP, LLC
5.48%
Andere
66.39%
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
9.51%
Fidelity Management & Research Company LLC
7.09%
BlackRock Institutional Trust Company, N.A.
5.94%
Redmile Group, LLC
5.60%
Enavate Sciences GP, LLC
5.48%
Andere
66.39%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
43.04%
Investment Advisor/Hedge Fund
24.45%
Hedge Fund
12.05%
Corporation
8.25%
Research Firm
5.75%
Individual Investor
1.69%
Venture Capital
0.89%
Bank and Trust
0.31%
Pension Fund
0.20%
Andere
3.36%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
326
85.20M
99.48%
+13.79M
2025Q1
320
89.38M
113.71%
+17.13M
2024Q4
278
64.18M
84.45%
+3.64M
2024Q3
252
62.39M
103.49%
+7.38M
2024Q2
228
58.25M
97.90%
+16.13M
2024Q1
182
46.83M
84.41%
+22.74M
2023Q4
113
32.29M
78.79%
+19.76M
2023Q3
82
6.26M
40.47%
+930.23K
2023Q2
81
5.83M
36.98%
+582.43K
2023Q1
95
4.18M
34.54%
-644.30K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
T. Rowe Price Investment Management, Inc.
7.55M
8.68%
+2.05M
+37.36%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.89M
4.47%
-26.90K
-0.69%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.11M
5.87%
+1.37M
+36.49%
Mar 31, 2025
Redmile Group, LLC
5.36M
6.16%
+533.16K
+11.04%
Mar 31, 2025
Enavate Sciences GP, LLC
4.77M
5.48%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
4.36M
5.01%
+3.67M
+533.09%
Mar 31, 2025
The Vanguard Group, Inc.
4.29M
4.93%
+1.29M
+43.20%
Mar 31, 2025
EcoR1 Capital, LLC
4.08M
4.69%
+200.00K
+5.16%
Mar 31, 2025
Opaleye Management Inc.
3.55M
4.08%
+1.51M
+74.02%
Mar 31, 2025
PRIMECAP Management Company
3.41M
3.92%
+3.13M
+1115.71%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Wed, Aug 6
Aktualisiert: Wed, Aug 6
Name
Anteil
Tema Oncology ETF
1.65%
iShares Genomics Immunology and Healthcare ETF
1.64%
WisdomTree BioRevolution Fund
1.01%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
ALPS Medical Breakthroughs ETF
0.55%
SPDR S&P Biotech ETF
0.2%
iShares Micro-Cap ETF
0.15%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
iShares Russell 2000 Growth ETF
0.05%
iShares US Tech Breakthrough Multisector ETF
0.04%
Mehr Anzeigen
Tema Oncology ETF
Anteil1.65%
iShares Genomics Immunology and Healthcare ETF
Anteil1.64%
WisdomTree BioRevolution Fund
Anteil1.01%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.86%
ALPS Medical Breakthroughs ETF
Anteil0.55%
SPDR S&P Biotech ETF
Anteil0.2%
iShares Micro-Cap ETF
Anteil0.15%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.13%
iShares Russell 2000 Growth ETF
Anteil0.05%
iShares US Tech Breakthrough Multisector ETF
Anteil0.04%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
